- Mednow has agreed to acquire London Pharmacare, expanding its specialty pharmacy services and expertise to include hepatology and liver disease treatment.
- Liver Care Canada or London Pharmacare generated C$21.3 million in revenue and C$2.1 million in gross profit in their most recent fiscal year.
The acquisition of Liver Care Canada and London Pharmacare complements the previous acquisition of InfusiCare Canada Inc., a specialty pharmacy and infusion clinic that is rapidly developing its model of being the pharmacy of the future.
The combined revenue of Liver Care Canada and London Pharmacare, InfusiCare Canada, and Medvisit in their most recent fiscal year was approximate C$33.6M, with a total gross profit of C$3.3M.
Liver Care Canada focuses on treating liver disease through an 8-clinic network that includes hepatologists, gastroenterology specialists, specialty nurse practitioners, registered nurses, also mobile care services.
The Targets acquisition will expand Mednow’s offering of specialty pharmacy and clinical services beyond those currently provided by Mednow’s wholly-owned subsidiary InfusiCare Canada Inc. (“InfusiCare”).
Liver Care Canada sees over 20,000 patients per year, both virtually and in person, and has a team of 12 specialty nurses, three of whom are nurse practitioners, as well as a history of treating over 5,000 Hepatitis C patients with corrective treatments.
Liver Care Canada takes a comprehensive approach to manage the liver disease, beginning with early detection and diagnostic services and progressing to direct access to treatments and supportive therapies such as weight loss and nutrition counseling.
The patient care team at Liver Care Canada acts as a patient care concierge, connecting patients to care based on their individual needs and care plans. The mobile clinics of Liver Care Canada also travel across Canada to assist patients with liver diseases.
“I believe Liver Care Canada will be capable to provide its services across Canada and enable more patients access care or receive their treatments safely and fast with virtual care and the ability to contact patients through Mednow’s platforms,” said Karim Ragheb, President of the Targets.